Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Positive topline results for Phase 3 trial of drug for allergic conjunctivitis
➤ Phase 2 trial of progesterone topical gel for DED begins
➤ Breakthrough Device Designation granted to remote glaucoma management system
➤ Glaukos enters into licensing agreement for presbyopia treatment
➤ Increase in laser vision correction procedures continues
➤ Guide on climate change and eye health
➤ ASCRS events
➤ FDA approves next-generation phaco machine
➤ Study: Endogenous compound reduces glaucomatous vision loss independent of IOP
➤ Successful transplant of stem cell-derived retinal ganglion cells in lab
➤ Phase 2 clinical trial for intravitreal dexamethasone implant
➤ ASCRS events
➤ Topline data from a Phase 3 study investigating first-in-class DED drop
➤ Research initiative focuses on new glaucoma treatments
➤ Phase 2 trial for oral treatment of diabetic retinopathy begins
➤ New SLT trial recruiting study sites
➤ ASCRS news and events
➤ Phase 2 clinical trial of minocycline for MGD
➤ Phase 2a study of drug-eluting contact lens for glaucoma
➤ Phase 1/2 results of RNA therapy for Usher syndrome, non-syndromic retinitis pigmentosa
➤ First regulatory approval for a therapeutic contact lens that treats ocular allergies
➤ Moist heat masks effective for signs, symptoms of dry eye, study finds
➤ ASCRS Journal Club on April 8
➤ FDA approves elements of artificial vision system for blind patients
➤ Expanded indication for MIGS device
➤ 5-year pivotal trial data for MIGS device
➤ Topline results from Phase 2 study of investigational MGD treatment
➤ FDA accepts NDA for fixed-combination mydriatic agent
➤ NDA accepted by FDA for dry eye nasal spray
➤ NDA submitted for drop to treat presbyopia
➤ Study to assess outcomes of ab interno canaloplasty
➤ Largest study of glaucoma genetics published
➤ Iridex and Topcon enter into strategic agreement
➤ COVID-19 vaccine update
➤ ASCRS Journal Club on March 11
Nathan Radcliffe, MD
Glaucoma Editor
Glaucoma Editor Nathan Radcliffe, MD, introduces the topics covered in the section, including early experience with Durysta, how other sustained therapies can benefit the glaucoma patient following cataract surgery, and how glaucoma care can be streamlined to keep everyone safe in the pandemic.
Durysta, the sustained-release bimatoprost implant, 10 mcg (Allergan), has been available with FDA approval in the U.S. market for a year now. EyeWorld spoke with two physicians who started offering it as an option to their patients to hear about their experience thus far.
EyeWorld spoke with several glaucoma specialists who discussed changes they’ve noticed in glaucoma as well as in their own practices due to the COVID-19 pandemic. They shared how they’ve adapted to continue patient care and described the changes they think are here to stay post-pandemic.
➤ PMA submitted to FDA for small-aperture IOL
➤ Preclinical results for new class of non-prostaglandin analogs for IOP lowering
➤ A Phase 2 clinical trial begins enrollment for topical presbyopia-correcting drop
➤ Home OCT technology used in clinical trial to reduce participant visits to offices
➤ ASCRS Journal Club on March 11
